United Therapeutics Corp. (UTHR)
512.70
+2.32
(+0.45%)
USD |
NASDAQ |
Sep 01, 16:00
512.63
-0.07
(-0.01%)
After-Hours: 20:00
United Therapeutics Research and Development Expense (Annual) : 550.00M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 550.00M |
| December 31, 2024 | 481.00M |
| December 31, 2023 | 408.00M |
| December 31, 2022 | 322.90M |
| December 31, 2021 | 410.00M |
| December 31, 2020 | 352.30M |
| December 31, 2019 | 373.80M |
| December 31, 2018 | 357.90M |
| December 31, 2017 | 264.60M |
| December 31, 2016 | 147.60M |
| December 31, 2015 | 245.10M |
| December 31, 2014 | 242.55M |
| December 31, 2013 | 299.35M |
| Date | Value |
|---|---|
| December 31, 2012 | 173.39M |
| December 31, 2011 | 180.02M |
| December 31, 2010 | 166.76M |
| December 31, 2009 | 122.19M |
| December 31, 2008 | 239.18M |
| December 31, 2007 | 83.35M |
| December 31, 2006 | 57.57M |
| December 31, 2005 | 36.05M |
| December 31, 2004 | 30.60M |
| December 31, 2003 | 35.42M |
| December 31, 2002 | 26.78M |
| December 31, 2001 | 32.59M |
| December 31, 2000 | 63.09M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Liquidia Corp. | 38.45M |
| MannKind Corp. | 66.35M |
| Vertex Pharmaceuticals, Inc. | 3.754B |
| Savara, Inc. | 81.40M |
| Exelixis, Inc. | 825.00M |